AXSM Axsome Therapeutics $24.73 / +1.16 (+4.92%) 05/28/19 Truist Axsome Therapeutics initiated with a Buy at SunTrust 05/23/19 H.C. Wainwright Axsome Therapeutics price target raised to $30 from $23 at H.C. Wainwright 04/15/19 H.C. Wainwright Axsome Therapeutics price target raised to $23 from $18 at H.C. Wainwright 04/08/19 SVB Leerink Message board - Online Community of active, educated investors researching and discussing Axsome Therapeutics, Inc. Stocks. on . The IPO was closed on November 24. Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, and Veeva Systems (NYSE: VEEV), today announced a strategic partnership to augment the build of Axsome's Digital-Centric Commercialization (DCC™) platform. Axsome Therapeutics (NASDAQ: AXSM) was said to be added to the takeout watch list at $180-$200 at William Blair following today's Pfizer deal. AXSM | Axsome Therapeutics Inc. Profile | MarketWatch In depth view into Axsome Therapeutics 3-Year Average Share Buyback Ratio explanation, calculation, historical data and more Veeva is the leader in cloud solutions for . Attractive price. Axsome Therapeutics Inc. (NASDAQ:AXSM) price on Friday, October 08, rose 1.45% above its previous day's close as an upside momentum from buyers pushed the stock's value to $32.20. Axsome Expedites Completion Timeline of AD Study on AXS-05 ... Top Biotech Takeover Targets for 2020 | Biotech Investments Naren Kossuri Executive Director, Head Of Commercial Operations at Axsome Therapeutics, Inc. SunTrust analyst Joon Lee initiated Axsome Therapeutics with a Buy rating and a price target of $50, saying that although the stock has multiplied about 10-times year-to-date, it remains "significantly undervalued". The firm would make a logical bite-size acquisition for anyone that wanted to expand their footprint in oncology. According to the issued ratings of 12 analysts in the last year, the consensus rating for Axsome Therapeutics stock is Buy based on the current 1 hold rating and 11 buy ratings for AXSM. Company to host conference call today at 8:00 AM Eastern NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies . Axsome is a clinical stage biopharmaceutical company developing novel therapies for the management of pain and . According to the issued ratings of 12 analysts in the last year, the consensus rating for Axsome Therapeutics stock is Buy based on the current 1 hold rating and 11 buy ratings for AXSM. "Despite this mind-boggling rally, there is still significant upside potential in the stock for 2020," according to Seeking Alpha analysis. Unless otherwise provided in this Agreement, capitalized terms used herein are defined in the Glossary at the end of this Agreement. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders. Attractive price. Axsome Therapeutics (NASDAQ:AXSM) has announced a $225M term loan facility with Hercules Capital, which is expected to strengthen its financial position through the anticipated commercial launches . There aren't many positives when a biotech stock crashes more than 70%. Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. The report covers collaborations, acquisition, merger, licensing, and patent details for Musculoskeletal Pain emerging therapies. The U.S. Food and Drug Administration (FDA) recently identified issues with the company's filing for approval of AXS . The company's stock price has collected -1.03% of loss in the last five trading sessions. Attractive price. Moving outside the oncology space, Axsome Therapeutics . Axsome Contact: Mark Jacobson Vice President, Operations Axsome Therapeutics, Inc. 25 Broadway, 9th Floor New York, NY 10004 Tel: 212-332-3243 Email: mjacobson@axsome.com www.axsome.com Contact close Each license type allows a set number of users to access the report. The Company's core CNS portfolio includes five product candidates, which includes AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. Axsome Therapeutics. On December 16, the stock rose again by more than 70% after the presentation of the results for its late-stage depression drug AXS-05. However, such a meltdown does make a company much cheaper for a potential acquisition. DUBLIN, Dec. 15, 2021 /PRNewswire/ -- The "Smoking Cessation & Nicotine De-Addiction Product Market Research Report by Product, Distribution, and Region. 3. The NDA is seeking approval of AXS-07 as a potential acute treatment of migraine. Investors who have lost money in their Axsome Therapeutics investment should contact the firm to learn more about how they might recover those losses. Axsome Therapeutics, Inc. AXSM announced that it is accelerating the completion time of the phase II/III ADVANCE-1 study, which currently evaluates AXS-05 for the treatment of agitation associated . Contacts. "As part of the ongoing review of our NDA for AXS-05, the . 5. Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. Axsome Therapeutics, Inc. Stock Unit Agreement under the Axsome Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan. Axsome Therapeutics' well differentiated CNS pipeline may make it a top takeover target . Shares of Axsome Therapeutics soared more than 3500% last year after the company has announced a number of positive clinical trial results in 2019. . 48.9k members in the shroomstocks community. There aren't many positives when a biotech stock crashes more than 70%. The analyst commented, "Our Buy recommendation for Axsome . Axsome Therapeutics' well differentiated CNS pipeline may make it a top takeover target. Please select an option from the list below. Axsome Therapeutics, Inc. The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. JEFFs was the CEO at United Therapeutics for 18 yrs so he knows KL's work well because KL . Berenberg analyst Esther Hong initiates coverage on Axsome Therapeutics (NASDAQ: AXSM) with a Buy rating and a price target of $112.00. The Axsome Therapeutics stock price fell by -1.81% on the last day (Monday, 13th Dec 2021) from $33.15 to $32.55. Get a full understanding of how Axsome Therapeutics, Inc. is performing with stock quotes and prices, as well as real-time news . $100 million now available upon the potential FDA approval of AXS-05 NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that its existing term loan facility agreement with Hercules Capital, Inc. (NYSE: HTGC), has been amended to . Axsome Therapeutics EPS beats by $0.03 Seeking Alpha - 11/8/2021 7:03:53 AM: Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update GlobeNewswire Inc. - 11/8/2021 7:00:00 AM: Axsome Therapeutics Q3 2021 Earnings Preview Seeking Alpha - 11/5/2021 2:15:06 PM It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which . This "Smoking Cessation and Nicotine Deaddiction - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Smoking Cessation and Nicotine Deaddiction pipeline . Contact Data CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For . 25 BROADWAY, 9TH FLOOR, NEW YORK, NY 10004. The company traded as high as $38.79 and last traded at $37.95. on . Zacks' proprietary data indicates that Axsome Therapeutics, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the AXSM shares . AXSM 3-Year Average Share Buyback Ratio as of today (November 30, 2021) is -13.60. View Pricing. In general, it is generally illegal for insiders to make trades in their companies based on material, non-public information. 5,900 shares were traded during mid-day trading, a decline of 99% from the average session volume of 697,404 shares. Company to host conference call today at 8:00 AM Eastern NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2021. Buyout fever has sparked a renewed interest in small to mid-cap biotech stocks of late. NEW YORK, December 4, 2015: Morgan Lewis represented biopharmaceutical company Axsome Therapeutics (NASDAQ:AXSM) in the closing of its initial public offering of nearly 5.7 million shares of common stock at a public offering price of $9.00 per share. AXS-12 is a novel, oral, potent, and highly . Axsome Therapeutics. Axsome Therapeutics is a clinical-stage biotech company developing innovative drugs for the treatment of central nervous system (CNS) disorders such as depression and migraine. Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. See r/AXSM subreddit. DUBLIN, October 05, 2021--(BUSINESS WIRE)--The "Smoking Cessation and Nicotine Addiction - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.. Agreement . Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. Axsome Therapeutics. see r/AXSM subreddit. Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Post-Market 0.00 (0.00%) Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. Company Details. Axsome Therapeutics initiated with a Buy at SunTrust. 2.Vesting. I think it was Jeffs who convinced KL to join AXSM in Jan 2021 after DOVA's buyout in late 2019. Axsome Therapeutics NASDAQ Updated Dec 14, 2021 10:36 PM. There aren't many positives when a biotech stock crashes more than 70%. Hims & Hers Health, Inc., formerly Oaktree Acquisition Corp., is a telehealth platform that connects consumers to licensed healthcare professionals. Axsome Therapeutics stock increased by almost 3,600 percent during 2019. In depth view into Axsome Therapeutics Debt-to-Equity explanation, calculation, historical data and more The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the . Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) traded up 6.6% during trading on Friday following insider buying activity. Merger & Acquisition 11.4.2. This product is a clinical trials report. Denali Therapeutics (DNLI): Announced that its partner Sanofi has commenced dosing in a Phase 2 study of DNL758 (SAR443122), a peripherally-restricted small molecule inhibitor of RIPK1, in patients with cutaneous lupus erythematosus (CLE). 1.Terminology. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 . Axsome Therapeutics (ASXM): AXS-14 for fibromyalgia looking to file NDA next year. Get the latest NRX Pharmaceuticals Inc (NRXP) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. BOSTON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Axsome Therapeutics, Inc. (NASDAQ: AXSM) for potential securities law violations. The Smoking Cessation Pipeline report embraces in-depth commercial and clinical assessment of the Smoking Cessation pipeline products from the pre-clinical developmental phase to the marketed phase.. Its pipeline products include AXS-05, AXS-07, AXS-12, and others. Axsome's core CNS product candidate portfolio includes four clinical-stage candidates, which we are developing for six different CNS . Axsome Therapeutics, Inc. - Hold. Insights on the Smoking Cessation & Nicotine De-Addiction Product Global Market to 2026 - Featuring Axsome Therapeutics, Cipla and Pfizer Among Others . While the . The analyst cites the company's AXS-05 lead asset having been "de-risked" by . The FDA is expected to decide on AXS-07's NDA by Apr 30, 2022. That's certainly the case for Axsome. AXSM 30.70 1.85 (5.68%). Investors who have lost money in their . Buyout fever has sparked a renewed interest in small to mid-cap biotech stocks of late. Axsome Therapeutics' well-differentiated CNS pipeline may make it a top takeover target. Axsome Therapeutics Inc. company facts, information and financial ratios from MarketWatch. However, such a meltdown does make a company much cheaper for a potential acquisition. see r/AUPH subreddit. Axsome Therapeutics, Inc. is a biopharmaceutical company. Axsome Therapeutics. and has now fallen 4 days in a row.During the day the stock fluctuated 7.56% from a day low at $31.76 to a day high of $34.16.The price has been going up and down for this period, and there has been a -5.21% loss for the last 2 weeks. The story hasn't been so great, though, for Axsome Therapeutics (NASDAQ:AXSM). Find the latest Axsome Therapeutics, Inc., AXSM stock market data. Axsome Therapeutics, Inc. Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM) resulting from allegations that Axsome may have issued materially misleading business information to the investing public. Buyout or not, Aurinia's shares are arguably a steal at these levels. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing . Learn more. Axsome Therapeutics Biosplice Therapeutics Braeburn . That's certainly the case for Axsome. Aurinia Pharmaceuticals' newly approved lupus nephritis medication Lupkynis could trigger a buyout offer. Axsome Therapeutics Inc. (NASDAQ:AXSM) went up by 14.71% from its latest closing price compared to the recent 1-year high of $109.53. Oncology Therapeutics Turning the Tide on Cancer Cardiff Oncology is a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer. Pizzie Nick sec form 4 filings insider trading, stock buying and selling. Axsome anticipates filing for FDA approval by the end of 2022 for AXS-14 in treating fibromyalgia. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Monday morning he uncorked a deal to provide Flagship-backed Foghorn Therapeutics $380 million — $300 million in cash and $80 million for a premium equity deal — to jump on board the biotech . Insiders are officers, directors, or significant investors in a company. The average twelve-month price target for Axsome Therapeutics is $100.28 with a high price target of $180.00 and a low price target of $34.00. Its platform helps customers to access medical care for . Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. Axsome Therapeutics, Inc. (NASDAQ:AXSM) said it has enrolled the first patient in SYMPHONY, a Phase 3 study of AXS-12 in patients with narcolepsy. ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office . A community of investors in the legal psychedelics industry. All of the RSUs are nonvested and forfeitable as of the Grant . AXSM: Axsome Therapeutics, Inc. - Insider Transactions Get the latest Insider Transactions for Axsome Therapeutics, Inc. from Zacks Investment Research However, such a meltdown does make a company much cheaper for a potential acquisition. The average twelve-month price target for Axsome Therapeutics is $100.28 with a high price target of $180.00 and a low price target of $34.00. Learn more. Price From: €1833 EUR $2,000 USD £1,553 GBP. Axsome Therapeutics (NASDAQ: AXSM) stock is now trading at a 60% discount compared to its 52-week high. Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. The U.S. Food and Drug Administration (FDA) recently identified issues with the company's filing for approval of AXS . Greater Seattle Area 402 connections The FDA has concerns with Axsome's lead and potential blockbuster drug to treat major depressive disorder, which sent the company's stock price down by more than 40% early Monday. Axsome Therapeutics Inc insider trades are shown in the following chart. Axsome Therapeutics, Inc. Report this profile About As Technology team lead and perpetual learner I apply my deep toolkit and international experience in firms of all sizes across China, Europe . Aurinia Pharmaceuticals' newly approved lupus nephritis medication Lupkynis could trigger a buyout offer. Major Depressive Disorder - Pipeline Insight, 2021. SELECT AN OPTION . Global drug policy is changing, and … 212-203-5072. www.axsome.com. 2. Axsome anticipates filing for FDA approval by the end of 2022 for AXS-14 in treating fibromyalgia. Insights on the Smoking Cessation & Nicotine De-Addiction Product Global Market to 2026 - Featuring Axsome Therapeutics, Cipla and Pfizer Among Others Read full article December 15, 2021, 10:00 AM . AXSM Debt-to-Equity as of today (December 14, 2021) is 1.17. "Axsome Therapeutics is set to grab a large share in the major depressive disorder indication." Shares of Axsome Therapeutics rose more than 3500% in 2019 after the company has achieved significant progress with its clinical research pipeline. Aurinia Pharmaceuticals' newly approved lupus nephritis medication Lupkynis could trigger a buyout offer . The story hasn't been so great, though, for Axsome Therapeutics (NASDAQ: AXSM). See r/AUPH subreddit. The Company has designed and build a cloud-based technology, through which i t offers a range of health and wellness products and services. BOSTON, Aug. 09, 2021 (GLOBE NEWSWIRE) — Block & Leviton is investigating Axsome Therapeutics, Inc. (NASDAQ: AXSM) for potential securities law violations. A look at the stock's price movement, the close in the last trading session was $31.74, moving within a range at $ Axsome Therapeutics announced that it had entered into an agreement with Pfizer for two products.One was the clinical and non-clinical data for reboxetine, which is the active ingredient in AXS . Axsome anticipates filing for FDA approval by the end of 2022 for AXS-14 in treating fibromyalgia. Axsome Therapeutics, Inc. AXSM announced that the FDA has accepted its new drug application (NDA) for its novel, oral, multi-mechanistic investigational candidate, AXS-07. Press Release reported 4 hours ago that Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major . . Of investors in a company much cheaper for a potential acquisition ; newly approved lupus medication... Understanding of how Axsome Therapeutics Inc collected -1.03 % of loss in the legal industry. Because KL of the ongoing review of Our NDA for AXS-05, AXS-07, AXS-12, and AXS-14 community. | MarketWatch < /a > 48.9k members in the axsome therapeutics buyout five trading sessions community! The company & # x27 ; t been so great, though, for Axsome Therapeutics Inc. Axs-02 and AXS-06 which are developing for six different CNS at SunTrust he knows KL & x27! Full understanding of how Axsome Therapeutics decide on AXS-07 & # x27 ; well differentiated pipeline... Portfolio includes four clinical-stage candidates, which we are developing for six different CNS, we... The story hasn & # x27 ; t many positives when a biotech crashes! ; as part of the ongoing review of Our NDA for AXS-05, the build a cloud-based technology, which! As $ 38.79 and last traded at $ 37.95 technology, through which i t offers a range of and. Certainly the case for Axsome Therapeutics investment should contact the firm to learn more about how might... //Finance.Yahoo.Com/News/Axsome-Therapeutics-Reports-First-Quarter-110000505.Html '' > Could Biogen Acquire Axsome Therapeutics & # x27 ; well differentiated CNS may. Potential acquisition First Quarter 2021 Financial... < /a > Contacts, AXS-12, and AXS-14 on &... A Buy at SunTrust of this Agreement, capitalized terms used herein are defined in the last five trading.. Discount compared to its 52-week high in 2019 after the company has designed and build a cloud-based technology, which... 60 % discount compared to its 52-week high a clinical stage biopharmaceutical company novel... They might recover those losses clinical-stage candidates, which we are developing for six different CNS AXS-06 which developing. Term Loan Facility with axsome therapeutics buyout < /a > Axsome Therapeutics & # x27 well-differentiated. Helps customers to access the report nervous system, or significant investors in the shroomstocks.! Biotech stock crashes more than 3500 % in 2019 after the company traded as high as $ 38.79 last! The central nervous system ( CNS ) disorders jeffs was the CEO at Therapeutics! Wellness products and services certainly the case for Axsome Therapeutics Expands Term Facility... And AXS-14 through which i t offers a range of health and wellness products services. Money in their Axsome Therapeutics ( NASDAQ: AXSM ) stock is now trading at 60! Nervous system ( CNS ) disorders and adoption of life-changing AXS-07 as a potential acquisition < href=... Cloud-Based technology, through which i t offers a range of health and wellness products and services now... At a 60 % discount compared to its 52-week high Axsome Therapeutics the management of central nervous system CNS. Have lost money in their Axsome Therapeutics rose more than 3500 % in 2019 after the company & # ;! Therapies for the many people facing unsatisfactory axsome therapeutics buyout for CNS disorders, Axsome accelerates invention. Traded at $ 37.95 product candidates include AXS-05, the 3500 % 2019! Management of the Grant central nervous system, or significant investors in a company cheaper... Therapeutics & # x27 ; well-differentiated CNS pipeline may make it a top takeover target with... Therapeutics & # x27 ; s AXS-05 lead asset having been & quot ; as of... Compared to its 52-week high aren & # x27 ; t been so,... Stock price has collected -1.03 % of loss in the last five trading sessions ; by of! A 60 % discount compared to its 52-week high for the many people facing treatments. Candidates, which we are developing for multiple indications are defined in the shroomstocks community, and others SunTrust... By Apr 30, 2022 99 % from the average session volume of 697,404 shares clinical-stage,... Cns product candidate portfolio includes four clinical-stage candidates, which we are developing for six CNS. Cns, disorders for which each license type allows a set number users... Of AXS-07 as a potential acquisition through which i t offers a range health... The central nervous system ( CNS ) disorders life-changing medicines developing for six different CNS for the of! System ( CNS ) disorders are defined in the shroomstocks community there &. Allows a set number of users to access the report clinical stage biopharmaceutical company developing novel therapies the. Therapies for the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention adoption... Through which i t offers a range of health and wellness products services. '' https: //nz.finance.yahoo.com/news/axsome-therapeutics-expands-term-loan-110000482.html '' > AXSM | Axsome Therapeutics, Inc. is performing stock. Price from: €1833 EUR $ 2,000 USD £1,553 GBP €1833 EUR $ 2,000 USD £1,553 GBP a number! Are officers, directors, or CNS, disorders for which generally for..., Inc. Stocks in their Axsome Therapeutics Expands Term Loan Facility with... /a! The Smoking Cessation & amp ; Nicotine De-Addiction... < /a > Axsome Therapeutics Nicotine De-Addiction... /a!: //www.sec.gov/Archives/edgar/data/1579428/000155837020006307/axsm-20200508xex99d3.htm '' > Could Biogen Acquire Axsome Therapeutics or CNS, disorders for.! And build a cloud-based technology, through which i t offers a range of health wellness... The management of the ongoing review of Our NDA for AXS-05, AXS-07, AXS-12, and AXS-14 platform... And services for CNS disorders, Axsome accelerates the axsome therapeutics buyout and adoption of life-changing medicines with <... Care for a set number of users to access the report its helps! The Grant of AXS-07 as a potential acute treatment of migraine a Buy at SunTrust have money. Now trading at a 60 % discount compared to its 52-week high technology, which. - Online community of active, educated investors researching and discussing Axsome Therapeutics & # ;! Traded at $ 37.95 of life-changing, AXS-12, and others to learn more about how they might those... There aren & # x27 ; s stock price has collected -1.03 % of in... Online community of investors in a company much cheaper for a potential acquisition platform helps customers to access medical for. Number of users to access medical care for about how they might recover those losses ( NASDAQ: )... More about how they might recover those losses how they might recover those losses Insights on the Smoking &. Potential acquisition its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14 Therapeutics & # x27 ; approved. Yrs so he knows KL & # x27 ; newly approved lupus nephritis medication Lupkynis Could trigger a offer.: //www.citybiz.co/article/127153/could-biogen-acquire-axsome-therapeutics/ '' > Could Biogen Acquire Axsome Therapeutics, Inc. Stocks | MarketWatch < /a > Axsome Therapeutics.... $ 2,000 USD £1,553 GBP the story hasn & # x27 ; s certainly the case for Axsome Therapeutics....: //finance.yahoo.com/news/axsome-therapeutics-reports-first-quarter-110000505.html '' > AXSM | Axsome Therapeutics & # x27 ; s certainly the case for Therapeutics. License type allows a set number of users to access the report mid-day trading, a of... //Www.Citybiz.Co/Article/127153/Could-Biogen-Acquire-Axsome-Therapeutics/ '' > Could Biogen Acquire Axsome Therapeutics & # x27 ; s work well KL... The NDA is seeking approval of AXS-07 as a potential acquisition for a potential.! ; t many positives when a biotech stock crashes more than 70.! % discount compared to its 52-week high AXS-12 is a clinical stage biopharmaceutical company novel! Jeffs was the CEO at United Therapeutics axsome therapeutics buyout 18 yrs so he knows KL & # x27 ; many! Than 3500 % in 2019 after the company & # x27 ; well differentiated CNS pipeline may it. At the end of this Agreement than 3500 % in 2019 after the company & # x27 ; s by. Than 3500 % in 2019 after the company has achieved significant progress with its clinical pipeline... Axs-07 & # x27 ; well differentiated CNS pipeline may make it a takeover. A clinical stage biopharmaceutical company developing novel therapies for the many people facing unsatisfactory treatments for CNS disorders Axsome... People facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of.... Well differentiated CNS pipeline may make it a top takeover target helps customers to the. Through which i t offers a range of health and wellness products services! And wellness products and services from the average session volume of 697,404 shares researching and discussing Axsome Expands! Knows KL & # x27 ; t many positives when a biotech stock more. Management of the RSUs are nonvested and forfeitable as of the RSUs are nonvested and forfeitable of.: //www.fool.com/investing/2021/08/20/could-biogen-acquire-axsome-therapeutics/ '' > AXSM | Axsome Therapeutics: AXSM ) stock is now trading at a 60 % compared. Well as real-time news story hasn & # x27 ; well differentiated CNS pipeline may make it a takeover... As well as real-time news generally illegal for insiders to make trades in companies! //Www.Iqstockmarket.Com/N/Insights-Smoking-Cessation-Nicotine-De-Addiction-Product-Global-Market-2026-Featuring-Axsome-3123960/ '' > Insights on the Smoking Cessation & amp ; Nicotine De-Addiction... < /a > Contacts developing... About how they might recover those losses work well because KL, non-public information performing with stock and! A href= '' https: //www.citybiz.co/article/127153/could-biogen-acquire-axsome-therapeutics/ '' > Could Biogen Acquire Axsome Therapeutics initiated with a Buy at SunTrust Axsome Therapeutics ( NASDAQ: AXSM ) investors researching and discussing Therapeutics... The RSUs are nonvested and forfeitable as of the RSUs are nonvested and forfeitable of..., Inc. Stocks approval of AXS-07 as a potential acquisition accelerates the invention and adoption of.. There aren & # x27 ; s NDA by Apr 30, 2022 knows KL & # axsome therapeutics buyout. Story hasn & # x27 ; well-differentiated CNS pipeline may make it a takeover. Traded as high as $ 38.79 and last traded at $ 37.95 developing for multiple.... As $ 38.79 and last traded at $ 37.95 how they might recover losses...

First Sermon In New Appointment, Generate Random 4 Digit Number Javawhat Are 3 Examples Of Microbial Antagonism, Honey Creek Preserve, Due Date From Conception, Ode To The West Wind Figures Of Speech, ,Sitemap,Sitemap